000902002 001__ 902002
000902002 005__ 20211130111101.0
000902002 0247_ $$2doi$$a10.3233/JPD-202278
000902002 0247_ $$2ISSN$$a1877-7171
000902002 0247_ $$2ISSN$$a1877-718X
000902002 0247_ $$2Handle$$a2128/28890
000902002 0247_ $$2altmetric$$aaltmetric:93078592
000902002 0247_ $$2pmid$$apmid:33074192
000902002 0247_ $$2WOS$$aWOS:000618063800028
000902002 037__ $$aFZJ-2021-03965
000902002 041__ $$aEnglish
000902002 082__ $$a610
000902002 1001_ $$0P:(DE-HGF)0$$aJost, Stefanie T.$$b0
000902002 245__ $$aSubthalamic Stimulation Improves Quality of Sleep in Parkinson Disease: A 36-Month Controlled Study
000902002 260__ $$aAmsterdam$$bIOS Press$$c2021
000902002 3367_ $$2DRIVER$$aarticle
000902002 3367_ $$2DataCite$$aOutput Types/Journal article
000902002 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1636032118_17824
000902002 3367_ $$2BibTeX$$aARTICLE
000902002 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000902002 3367_ $$00$$2EndNote$$aJournal Article
000902002 520__ $$aBackground:Sleep disturbances and neuropsychiatric symptoms are some of the most common nonmotor symptoms in Parkinson’s disease (PD). The effect of subthalamic stimulation (STN-DBS) on these symptoms beyond a short-term follow-up is unclear.Objective:To examine 36-month effects of bilateral STN-DBS on quality of sleep, depression, anxiety, and quality of life (QoL) compared to standard-of-care medical therapy (MED) in PD.Methods:In this prospective, controlled, observational, propensity score matched, international multicenter study, we assessed sleep disturbances using the PDSleep Scale-1 (PDSS), QoL employing the PDQuestionnaire-8 (PDQ-8), motor disorder with the Scales for Outcomes in PD (SCOPA), anxiety and depression with the Hospital Anxiety and Depression Scale (HADS), and dopaminergic medication requirements (LEDD). Within-group longitudinal outcome changes were tested using Wilcoxon signed-rank and between-group longitudinal differences of change scores with Mann-Whitney U tests. Spearman correlations analyzed the relationships of outcome parameter changes at follow-up.Results:Propensity score matching applied on 159 patients (STN-DBS n = 75, MED n = 84) resulted in 40 patients in each treatment group. At 36-month follow-up, STN-DBS led to significantly better PDSS and PDQ-8 change scores, which were significantly correlated. We observed no significant effects for HADS and no significant correlations between change scores in PDSS, HADS, and LEDD.Conclusions:We report Class IIb evidence of beneficial effects of STN-DBS on quality of sleep at 36-month follow-up, which were associated with QoL improvement independent of depression and dopaminergic medication. Our study highlights the importance of sleep for assessments of DBS outcomes.
000902002 536__ $$0G:(DE-HGF)POF4-5251$$a5251 - Multilevel Brain Organization and Variability (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000902002 588__ $$aDataset connected to DataCite
000902002 7001_ $$0P:(DE-HGF)0$$aRay Chaudhuri, K.$$b1
000902002 7001_ $$0P:(DE-HGF)0$$aAshkan, Keyoumars$$b2
000902002 7001_ $$0P:(DE-HGF)0$$aLoehrer, Philipp A.$$b3
000902002 7001_ $$0P:(DE-HGF)0$$aSilverdale, Monty$$b4
000902002 7001_ $$0P:(DE-HGF)0$$aRizos, Alexandra$$b5
000902002 7001_ $$0P:(DE-HGF)0$$aEvans, Julian$$b6
000902002 7001_ $$0P:(DE-HGF)0$$aPetry-Schmelzer, Jan Niklas$$b7
000902002 7001_ $$0P:(DE-Juel1)131613$$aBarbe, Michael T.$$b8
000902002 7001_ $$0P:(DE-HGF)0$$aSauerbier, Anna$$b9
000902002 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon R.$$b10
000902002 7001_ $$0P:(DE-HGF)0$$aVisser-Vandewalle, Veerle$$b11
000902002 7001_ $$0P:(DE-HGF)0$$aAntonini, Angelo$$b12
000902002 7001_ $$0P:(DE-HGF)0$$aMartinez-Martin, Pablo$$b13
000902002 7001_ $$0P:(DE-HGF)0$$aTimmermann, Lars$$b14
000902002 7001_ $$0P:(DE-HGF)0$$aDafsari, Haidar S.$$b15$$eCorresponding author
000902002 773__ $$0PERI:(DE-600)2599550-9$$a10.3233/JPD-202278$$gVol. 11, no. 1, p. 323 - 335$$n1$$p323 - 335$$tJournal of Parkinson's Disease$$v11$$x1877-718X$$y2021
000902002 8564_ $$uhttps://juser.fz-juelich.de/record/902002/files/Jost_2021_J%20Parkinson%20Dis_Subthalamic%20Stimulation%20improves%20quality%20of%20sleep%20in%20PD_accepted%20manuscript.docx$$yOpenAccess
000902002 8564_ $$uhttps://juser.fz-juelich.de/record/902002/files/jpd_2021_11-1_jpd-11-1-jpd202278_jpd-11-jpd202278.pdf$$yRestricted
000902002 909CO $$ooai:juser.fz-juelich.de:902002$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000902002 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b10$$kFZJ
000902002 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5251$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000902002 9141_ $$y2021
000902002 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-28
000902002 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-28
000902002 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-28
000902002 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ PARKINSON DIS : 2019$$d2021-01-28
000902002 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-28
000902002 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000902002 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000902002 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-28
000902002 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ PARKINSON DIS : 2019$$d2021-01-28
000902002 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000902002 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-28
000902002 920__ $$lyes
000902002 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000902002 980__ $$ajournal
000902002 980__ $$aVDB
000902002 980__ $$aUNRESTRICTED
000902002 980__ $$aI:(DE-Juel1)INM-3-20090406
000902002 9801_ $$aFullTexts